A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 400 shares of BDTX stock, worth $1,316. This represents 0.0% of its overall portfolio holdings.

Number of Shares
400
Previous 7,700 94.81%
Holding current value
$1,316
Previous $39,000 97.44%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.65 - $7.39 $30,490 - $48,456
-6,557 Reduced 59.15%
4,529 $21,000
Q1 2024

May 15, 2024

SELL
$2.67 - $5.74 $292,842 - $629,557
-109,679 Reduced 90.82%
11,086 $56,000
Q4 2023

Feb 14, 2024

BUY
$1.77 - $3.03 $180,529 - $309,041
101,994 Added 543.36%
120,765 $339,000
Q3 2023

Nov 14, 2023

SELL
$2.87 - $4.99 $3.43 Million - $5.97 Million
-1,196,637 Reduced 98.46%
18,771 $53,000
Q2 2023

Aug 14, 2023

BUY
$1.43 - $6.18 $940,420 - $4.06 Million
657,637 Added 117.9%
1,215,408 $6.14 Million
Q1 2023

May 15, 2023

SELL
$1.35 - $3.14 $291,636 - $678,324
-216,027 Reduced 27.92%
557,771 $1.05 Million
Q4 2022

Feb 14, 2023

BUY
$1.27 - $2.51 $931,099 - $1.84 Million
733,149 Added 1803.61%
773,798 $1.39 Million
Q3 2022

Nov 14, 2022

SELL
$1.68 - $4.01 $76,095 - $181,632
-45,295 Reduced 52.7%
40,649 $69,000

Others Institutions Holding BDTX

About Black Diamond Therapeutics, Inc.


  • Ticker BDTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,339,500
  • Market Cap $120M
  • Description
  • Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...
More about BDTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.